AN2 Therapeutics, Inc.
ANTXNasdaq
$4.68
↑ +0.2%Jul 17 close · end-of-day
Price
1Y↑ +333.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$159.4M
Enterprise Value
$74.1M
P/E
—
P/S
—
P/B
1.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$34.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-42.3%
ROIC
—
Debt / Equity
—
Net Cash
$85.3M
Return 1Y
+329.4%
Company profile
AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
- CEO
- Eric Easom
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- an2therapeutics.com
Management & directors
- Eizen Joshua MSee Remarks
- Williams Sarah JoannePrincipal Accounting Officer
- Chanda SanjayChief Development Officer
- Day LucyChief Financial Officer
- Easom EricChief Executive Officer
- Prior Stephen DavidChief Strategy Officer
Roles derived from SEC Form 4 filings.
Earnings
ANTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.29↓ -17.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$21.6M | -$42.3M | -$69.6M | -$56.8M | -$38.1M |
| Net income | -$21.5M | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
| Diluted EPS | -$10.64 | -$2.79 | -$2.74 | -$1.72 | -$1.16 |
| Operating cash flow | -$20.5M | -$33.5M | -$53.3M | -$49.3M | -$29.8M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.9M | -$14.0M | -$8.6M | -$11.5M | -$7.2M | -$10.0M | -$9.3M | -$10.6M |
| Net income | -$14.4M | -$12.7M | -$7.5M | -$10.6M | -$6.5M | -$9.4M | -$8.7M | -$10.0M |
| Diluted EPS | -$0.48 | -$0.43 | -$0.25 | -$0.35 | -$0.21 | -$0.31 | -$0.29 | -$0.29 |
| Operating cash flow | -$14.4M | -$12.0M | -$5.3M | -$10.6M | -$7.6M | -$6.4M | -$5.2M | -$12.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 21, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Aziz Kabeer | Award | 2,852 | $0.00 | $0.00 | filing |
| 2026-07-10 | Martin Patricia A. | Award | 766 | $0.00 | $0.00 | filing |
| 2026-07-10 | Marks Gilbert Lynn | Award | 2,789 | $0.00 | $0.00 | filing |
| 2026-07-08 | Eizen Joshua M· See Remarks | Sale | 5,945 | $4.17 | $24,802.54 | filing |
| 2026-05-29 | Williams Sarah Joanne· Principal Accounting Officer | Sale | 265 | $4.43 | $1,173.95 | filing |
| 2026-04-10 | Aziz Kabeer | Award | 3,775 | $0.00 | $0.00 | filing |
| 2026-04-10 | Marks Gilbert Lynn | Award | 3,775 | $0.00 | $0.00 | filing |
| 2026-04-10 | Martin Patricia A. | Award | 1,192 | $0.00 | $0.00 | filing |
| 2026-03-03 | Williams Sarah Joanne· Principal Accounting Officer | Sale | 327 | $1.06 | $346.62 | filing |
| 2026-02-20 | Williams Sarah Joanne· Principal Accounting Officer | Award | 48,375 | $0.00 | $0.00 | filing |
| 2026-02-20 | Eizen Joshua M· See Remarks | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Eizen Joshua M· See Remarks | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Day Lucy· Chief Financial Officer | Award | 38,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Day Lucy· Chief Financial Officer | Award | 38,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Williams Sarah Joanne· Principal Accounting Officer | Award | 48,375 | $0.00 | $0.00 | filing |
| 2026-02-20 | Easom Eric· Chief Executive Officer | Award | 112,250 | $0.00 | $0.00 | filing |
| 2026-02-20 | Easom Eric· Chief Executive Officer | Award | 112,250 | $0.00 | $0.00 | filing |
| 2026-02-20 | Chanda Sanjay· Chief Development Officer | Award | 38,000 | $0.00 | $0.00 | filing |
| 2026-01-12 | Aziz Kabeer | Award | 11,560 | $0.00 | $0.00 | filing |
| 2026-01-12 | Martin Patricia A. | Award | 3,650 | $0.00 | $0.00 | filing |
| 2026-01-12 | Marks Gilbert Lynn | Award | 11,560 | $0.00 | $0.00 | filing |
| 2026-01-06 | Eizen Joshua M· See Remarks | Sale | 6,931 | $1.01 | $7,014.17 | filing |
| 2026-01-06 | Chanda Sanjay· Chief Development Officer | Sale | 5,956 | $1.01 | $6,027.47 | filing |
| 2026-01-06 | Day Lucy· Chief Financial Officer | Sale | 5,512 | $1.01 | $5,578.14 | filing |
| 2026-01-06 | Prior Stephen David· Chief Strategy Officer | Sale | 2,858 | $1.01 | $2,892.30 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.